观察组织再生膜修复耳鼻咽喉头颈外科软组织缺损的安全性和疗效性的前瞻、开放、单组临床试验--修复鼻黏膜缺损的临床试验

注册号:

Registration number:

ChiCTR-OPC-16008867 

最近更新日期:

Date of Last Refreshed on:

2016-07-21 16:48:06 

注册时间:

Date of Registration:

2016-07-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

观察组织再生膜修复耳鼻咽喉头颈外科软组织缺损的安全性和疗效性的前瞻、开放、单组临床试验--修复鼻黏膜缺损的临床试验

Public title:

A prospective, open, one slingle set of clincial trail to observe the tissue regeneration membrane repair soft tissue defect of safety and efficacy that in otolaryngology head and neck surgery.A clinical trial of repairing defects of nasal mucosa.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

观察组织再生膜修复耳鼻咽喉头颈外科软组织缺损的安全性和疗效性的前瞻、开放、单组临床试验--修复鼻黏膜缺损的临床试验

Scientific title:

A prospective, open, one slingle set of clincial trail to observe the tissue regeneration membrane repair soft tissue defect of safety and efficacy that in otolaryngology head and neck surgery.A clinical trial of repairing defects of nasal mucosa.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

尹立强 

研究负责人:

王永芳 

Applicant:

Liqiang Yin 

Study leader:

Yongfang Wang 

申请注册联系人电话:

Applicant telephone:

+86 0535-6397063

研究负责人电话:

Study leader's
telephone:

+86 15063856165

申请注册联系人传真 :

Applicant Fax:

+86 0535-6931900

研究负责人传真:

Study leader's fax:

+86 0535-6931900

申请注册联系人电子邮件:

Applicant E-mail:

yinlq@zhenghai.com

研究负责人电子邮件:

Study leader's E-mail:

crawyf@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

烟台经济技术开发区衡山路10号

研究负责人通讯地址:

烟台经济技术开发区衡山路10号

Applicant address:

10 Hengshan Road, Yantai Economic and Technological Development Zone, Yantai, Shandong, China

Study leader's address:

10 Hengshan Road, Yantai Economic and Technological Development Zone, Yantai, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

264006

研究负责人邮政编码:

Study leader's postcode:

264006

申请人所在单位:

烟台正海生物科技股份有限公司

Applicant's institution:

Yantai Zhenghai Bio-Tech Co., Ltd.

研究负责人所在单位:

烟台正海生物科技股份有限公司

Affiliation of the Leader:

Yantai Zhenghai Bio-Tech Co., Ltd.

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-6

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院临床试验伦理分委员会

Name of the ethic committee:

West China Hospital of Sichuan University clinical trial ethics committee

伦理委员会批准日期:

Date of approved by ethic committee:

2016-06-15 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxuexiang, Chengdu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

烟台

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

烟台正海生物科技股份有限公司

具体地址:

烟台经济技术开发区衡山路10号

Institution
hospital:

Yantai Zhenghai Bio-Tech Co., Ltd.

Address:

10 Hengshan Road, Yantai Economic and Technological Development Zone, Yantai, Shandong, China

经费或物资来源:

烟台正海生物科技股份有限公司

Source(s) of funding:

Yantai Zhenghai Bio-Tech Co., Ltd.

研究疾病:

鼻黏膜缺损  

Target disease:

defects of nasal mucosa

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

观察组织再生膜修复鼻黏膜缺损的安全性及有效性。  

Objectives of Study:

To observe the safety and effecacy of the tissue regeneration membrane to repair defects of nasal mucosa.

药物成份或治疗方案详述:

I型胶原 

Description for medicine or protocol of treatment in detail:

Type I collegen. 

纳入标准:

Inclusion criteria

排除标准:

1.严重肝肾功能障碍、代谢综合症、心血管疾病等全身疾病不能耐受手术者;
2.妊娠期或哺乳期的女性以及计划在研究期间妊娠的患者;
3.对胶原产品过敏者;
4.长期使用免疫抑制剂者;
5.不能耐受全身麻醉的患者;
6.有精神性疾病或精神异常者;
7.依从性差,无法按期完成随访者;
8.有外科手术禁忌症患者;
9.其他经研究者判定不符合入选条件的患者。

Exclusion criteria:

1. Severe liver and kidney dysfunction, metabolic syndrome, cardiovascular disease such as systemic disease cannot tolerate surgery;
2. During pregnancy or lactation women and patients with plan of pregnancy during the study period;
3. Allergy of collagen products;
4. The long-term use of immune inhibitor;
5. Can't tolerance of patients with general anesthesia;
6. With mental illness or mental abnormal;
7. Poor compliance, can't do with according to the visitor;
8 patients with surgical contraindication;
9. Other researchers determine does not comply with the conditions of patients.

研究实施时间:

Study execute time:

From 2016-07-25 00:00:00 To 2017-02-28 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-07-25 00:00:00 To 2016-11-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

10

Group:

treatment group

Sample size:

干预措施:

覆盖组织再生膜

干预措施代码:

Intervention:

Covering tissue regeneration membrane

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

完全上皮化率

指标类型:

主要指标

Outcome:

Complete epithelial change rate

Type:

Primary indicator

测量时间点:

术后10周

测量方法:

通过鼻内镜采集的照片信息进行评估。评估标准:黏膜薄而光滑,与骨壁紧密连接,遗留的骨壁在黏膜的紧密覆盖下显示清晰的各部隆起,窦口畅通。

Measure time point of outcome:

The tenth week after surgery

Measure method:

To evaluate the complete epithelial change rate by nasal endoscopy information collection of photos. Evaluation criteria: mucosa thin and smooth, and bone wall closely connected, the legacy of the bone wall in various parts of the mucous membrane under the cover shows clear uplift, sinus mouth open.

指标中文名:

黏膜形态变化

指标类型:

次要指标

Outcome:

Mucosal morphology change

Type:

Secondary indicator

测量时间点:

术后1周、2周、3周、4周、5周、6周、7周、8周、10周、12周、14周

测量方法:

通过鼻内镜,使用Lund-Kennedy评分。

Measure time point of outcome:

The first week, second week, third week, fourth week, fifth week, sixth week, seventh week, eighth week, tenth week, twelfth week, fourteenth week

Measure method:

By nasal endoscopy, Lund - Kennedy score.

指标中文名:

黏膜转归3阶段百分比

指标类型:

次要指标

Outcome:

Mucous membrane outcome 3 phase percentage

Type:

Secondary indicator

测量时间点:

术前、术后1周、2周、3周、4周、5周、6周、7周、8周、10周、12周、14周

测量方法:

通过鼻内镜采集的照片信息进行评估。

Measure time point of outcome:

at before surgery,the first week, second week, third week, fourth week, fifth week, sixth week, seventh week, eighth week, tenth week, twelfth week and fourteenth week after surgery.

Measure method:

To evaluate the complete epithelial change rate by nasal endoscopy information collection of photos.

指标中文名:

病情主观评估

指标类型:

次要指标

Outcome:

Subjective evaluations

Type:

Secondary indicator

测量时间点:

术前、术后1周、2周、3周、4周、5周、6周、7周、8周、10周、12周、14周

测量方法:

视觉模拟量表

Measure time point of outcome:

at before surgery,the first week, second week, third week, fourth week, fifth week, sixth week, seventh week, eighth week, tenth week, twelfth week and fourteenth week after surgery.

Measure method:

visual analogue scale

指标中文名:

实验室检查

指标类型:

副作用指标

Outcome:

Laboratory tests

Type:

Adverse events

测量时间点:

术前、术后4周

测量方法:

血常规、血生化、凝血功能、免疫原检测、尿常规

Measure time point of outcome:

at before surgery, the fourth week after surgery.

Measure method:

Routine blood, blood biochemistry, blood coagulation function, immune, routine urine

指标中文名:

基本生命体征

指标类型:

副作用指标

Outcome:

Basic vital signs

Type:

Adverse events

测量时间点:

术前、术后4周、术后14周

测量方法:

血压、心率、呼吸、体温

Measure time point of outcome:

at before surgery, the fourth week and the fourteenth week after surgery.

Measure method:

Blood pressure, heart rate, breathing and body temperature

指标中文名:

其他不良事件发生率

指标类型:

副作用指标

Outcome:

The incidence of other adverse events

Type:

Adverse events

测量时间点:

术后1周、2周、3周、4周、5周、6周、7周、8周、10周、12周、14周

测量方法:

记录

Measure time point of outcome:

first week, second week, third week, fourth week, fifth week, sixth week, seventh week, eighth week, tenth week, twelfth week and fourteenth week after surgery.

Measure method:

record

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

no-random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以文献发表的形式公开数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

published literature.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

临床试验机构保存原始记录、病例记录表等数据至试验结束后十年,申办者保存临床试验资料至无该医疗器械使用时。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The clinical trail institution keep the original records, case records and other data to after ten years of off-test , the sponsor keep clinical trial data to without the medical equipment use.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-07-21 16:48:06